Only 9.1% of its patent portfolio mentions GLP-1 agonists or semaglutide, and 2.3% specifically targets weight loss
Excess adiposity is not passive storage
#GLP1 #FoodIndustry #Innovation #HealthAndWellness To view or add a comment, sign in - : The GLP-1 boom in the UK is no longer just a health story
Among members who were taking a GLP-1 at the time they were surveyed, less than a third indicated that they expected to be on the medication for the foreseeable future." Compare that to almost half of members who selected until I reach a target weight or other outcome. Similarly, when we asked our members what they found appealing about the idea of trying a GLP-1, they used terms like kickstart, jumpstart, and boost, all of which we believe suggests our members may view medication as short-term support on a long-term journey
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA et al